Thermo Fisher Scientific Inc. $TMO Shares Sold by Segment Wealth Management LLC

Segment Wealth Management LLC reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,559 shares of the medical research company’s stock after selling 141 shares during the quarter. Segment Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $632,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in TMO. Brighton Jones LLC increased its position in Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after acquiring an additional 988 shares during the period. Revolve Wealth Partners LLC boosted its stake in Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares in the last quarter. Vest Financial LLC boosted its stake in Thermo Fisher Scientific by 73.4% during the 1st quarter. Vest Financial LLC now owns 3,188 shares of the medical research company’s stock valued at $1,586,000 after purchasing an additional 1,349 shares in the last quarter. Signal Advisors Wealth LLC boosted its stake in Thermo Fisher Scientific by 7.2% during the 1st quarter. Signal Advisors Wealth LLC now owns 1,297 shares of the medical research company’s stock valued at $646,000 after purchasing an additional 87 shares in the last quarter. Finally, Eagle Rock Investment Company LLC boosted its stake in Thermo Fisher Scientific by 0.3% during the 1st quarter. Eagle Rock Investment Company LLC now owns 7,489 shares of the medical research company’s stock valued at $3,727,000 after purchasing an additional 26 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $543.88 on Friday. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97. The business has a fifty day simple moving average of $482.58 and a 200 day simple moving average of $447.27. The firm has a market cap of $205.37 billion, a price-to-earnings ratio of 31.46, a P/E/G ratio of 2.95 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same period last year, the company earned $5.37 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is currently 9.95%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on TMO shares. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the company an “outperform” rating in a research note on Tuesday, September 2nd. Raymond James Financial reaffirmed an “outperform” rating and set a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Barclays raised their price objective on Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an “overweight” rating in a research note on Thursday. Wells Fargo & Company reduced their price objective on Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a research note on Thursday, July 24th. Finally, Evercore ISI reduced their price objective on Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating for the company in a research note on Tuesday, July 8th. Fifteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $585.37.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company’s stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the transaction, the chief executive officer owned 113,762 shares in the company, valued at $56,937,881. The trade was a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock valued at $14,182,963 over the last quarter. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.